Clinical Trial Update: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial in previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation compares standard chemoimmunotherapy (FCR/BR) with severa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED